Stock Detail
YM BIOSCIENCES INC ORDINARY SHARES (CANADA)
Biotechnology
YMI @ Yahoo Finance | YMI Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.77 | $1.90 | $-0.03 | -1.67% | 0.00 | $1.80 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.79 | $1.75 | 2.07M | 206.58M | 738,917.33 | -9.78 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.96 | 1.87 | 1.81 | 1.72 | 1.66 |
Stock Profile
YM BioSciences, Inc., a development stage biopharmaceutical company, engages in the research and development of products primarily for the treatment of cancer. Its product candidates in the clinical stage of development include Tesmilifene, Nimotuzumab, AeroLEF, Norelin, and Radiotheracim. Tesmilifene, which is in phase III clinical trial, is a small molecule chemopotentiator for the treatment of metastatic and recurrent breast cancer. Nimotuzumab, which is in phase II clinical trial, is an antiepidermal growth factor humanized monoclonal antibody for the treatment of epithelial cancers. AeroLEF, which is in phase II clinical trials, is a proprietary formulation of both free and liposome-encapsulated fentanyl administered by pulmonary inhalation, is being developed for the treatment of severe and moderate acute pain and cancer pain. Norelin is a phase II clinical trial product for the treatment of sex-hormone dependent cancers. Radiotheracim is a radiolabelled humanized monoclonal antibody, targeting the epidermal growth factor receptor, and is being developed for the treatment of brain cancers. The company also has a portfolio of preclinical compounds shown to act as chemopotentiators while protecting normal cells. YM BioSciences has a collaborative agreement with Sanofi-Aventis to investigate the effect of combining tesmilifene and docetaxel for the treatment of women with rapidly progressing metastatic breast cancer. The company was founded in 1994 and is headquartered in Mississauga, Canada.